Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Oct

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Focus on Optimized Dosing of Ibrutinib Panel Discussion

FDA Approves First-Line Pirtobrutinib for CLL-SLL

Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy

FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality

Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence